The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid growing concerns over demand sustainability in the respiratory care sector, ResMed shares dropped 5.7% following price target cuts from major financial institutions. RBC Capital lowered its target for the medical device maker from $321 to $276 while maintaining an Outperform rating, and Wells Fargo trimmed its target to $225 from $227. These adjustments, according to reports, reflect analyst anxiety regarding potential headwinds for the company's sleep apnea product line.
Sign in to access this content
Sign InThe decline comes as investors weigh the impact of new weight-loss medications on the sleep apnea device market, leading analysts to adopt a more cautious stance on future growth prospects. Compared to peers in the med-tech space, RMD shares show high sensitivity to analyst revisions, with the new average price target settling near $250. Per market data, this selling pressure follows a period of relative strength, signaling a cooling of sentiment toward the broader sector.
RMD shares finished at $205.84 (close July 8, 2026), hovering near the daily low of $205.21, which suggests persistent technical pressure. With no immediate sector-specific catalysts in the upcoming economic calendar, traders will be watching current support levels to see if the stock can stabilize. Markets also remain attentive to any further management commentary regarding market share protection in the medium term.